Replies to post #133651 on Biotech Values

[iwfal]

MNTA -

You are assuming a GM % that assumes no other generic Copaxone competitors --- which is likely not going to be the case. If GM % is closer to 50% (driven by lower pricing), the BAX partnership terms are in line with the MNTA's mC terms.

Yes - the BAX agreement assumes substantial Copaxone competitors (e.g. either non-subs take large market share, or mBio is not the only subs generic) or some similar fairly big difference from any set of assumptions laid out on this board before today.